NovaBridge Biosciences
corporate_fare Company Profile
NovaBridge Biosciences (NASDAQ:NBP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for NBP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for NBP spans 6-K, 4, 20-F, SCHEDULE 13D/A.
Recent high-impact activity:
- NovaBridge Reports H1 2026 Loss of $37.9M, Cash Runway Through 2028
- Investor Deck Highlights $216M Cash, Givastomig Phase 3 Timeline, and VIS-101 Phase 2b Start
- NovaBridge Board Moves to Oust Director Xin Liu at September AGM
- NovaBridge Biosciences Appoints New CEO, Announces Multiple Board and Executive Changes
- NovaBridge's Lead Oncology Drug Givastomig Receives FDA Fast Track Designation
Financial Snapshot
Short Interest & Short Volume
17.09 days to coverFINRA reported short interest of 3,746,443 shares in NBP as of the September 15, 2026 settlement, a 4.5% increase from the prior period — about 17.1 days to cover at its recent average daily volume. On October 2, 2026, 45.0% of NBP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
NBP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.